S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Navidea Biopharmaceuticals Stock Forecast, Price & News

+0.02 (+0.93 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $2.17
50-Day Range
MA: $2.05
52-Week Range
Now: $2.17
Volume226,529 shs
Average Volume407,054 shs
Market Capitalization$60.73 million
P/E RatioN/A
Dividend YieldN/A
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a collaboration agreement with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Navidea Biopharmaceuticals logo


New Strong Sell Stocks for December 8th
December 8, 2020 |  finance.yahoo.com
Navidea Biopharmaceuticals
December 6, 2020 |  fool.com
Navidea to ring opening bell at NYSE
September 28, 2020 |  bizjournals.com
Navidea Biopharmaceuticals: Too Many Risks Involved
September 14, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
Previous SymbolNYSEMKT:NAVB
Year FoundedN/A



Sales & Book Value

Annual Sales$660,000.00
Book Value($0.05) per share


Net Income$-10,950,000.00
Net Margins-1,310.93%


Market Cap$60.73 million
Next Earnings Date3/10/2021 (Estimated)


Overall MarketRank

1.68 out of 5 stars

Medical Sector

288th out of 1,972 stocks

Diagnostic Substances Industry

6th out of 32 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.02 (+0.93 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

Is Navidea Biopharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Navidea Biopharmaceuticals stock.
View analyst ratings for Navidea Biopharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Navidea Biopharmaceuticals?

Wall Street analysts have given Navidea Biopharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Navidea Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a drop in short interest during the month of February. As of February 12th, there was short interest totaling 166,200 shares, a drop of 33.0% from the January 28th total of 248,100 shares. Based on an average daily volume of 305,700 shares, the short-interest ratio is presently 0.5 days.
View Navidea Biopharmaceuticals' Short Interest

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Navidea Biopharmaceuticals

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) posted its quarterly earnings data on Thursday, November, 12th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.30 million. Navidea Biopharmaceuticals had a negative net margin of 1,310.93% and a negative trailing twelve-month return on equity of 372.59%.
View Navidea Biopharmaceuticals' earnings history

How has Navidea Biopharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Navidea Biopharmaceuticals' stock was trading at $0.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NAVB stock has increased by 126.0% and is now trading at $2.17.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NAVB?

2 Wall Street analysts have issued 12 month target prices for Navidea Biopharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Navidea Biopharmaceuticals' share price to reach $7.50 in the next year. This suggests a possible upside of 245.6% from the stock's current price.
View analysts' price targets for Navidea Biopharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the following people:
  • Mr. Jed A. Latkin, CEO, COO, CFO & Director (Age 47, Pay $658.74k)
  • Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer (Age 53, Pay $243.79k)
  • Erika Gibson, Director of Fin. & Admin.
  • Mr. William J. Regan, Chief Compliance Officer (Age 69)
  • Mr. Joel Harrison Kaufman, Chief Bus. Officer

Who are some of Navidea Biopharmaceuticals' key competitors?

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), CorMedix (CRMD), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

Who are Navidea Biopharmaceuticals' major shareholders?

Navidea Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.21%), Allred Capital Management LLC (0.20%) and HighTower Advisors LLC (0.14%). Company insiders that own Navidea Biopharmaceuticals stock include Claudine Bruck, Jed Latkin, John K Jr Scott, Malcolm G Witter and Sarah Kathryn Rouan.
View institutional ownership trends for Navidea Biopharmaceuticals

Which institutional investors are selling Navidea Biopharmaceuticals stock?

NAVB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Allred Capital Management LLC.
View insider buying and selling activity for Navidea Biopharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Navidea Biopharmaceuticals stock?

NAVB stock was acquired by a variety of institutional investors in the last quarter, including HighTower Advisors LLC. Company insiders that have bought Navidea Biopharmaceuticals stock in the last two years include Claudine Bruck, Jed Latkin, John K Jr Scott, Malcolm G Witter, and Sarah Kathryn Rouan.
View insider buying and selling activity for Navidea Biopharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $2.17.

How much money does Navidea Biopharmaceuticals make?

Navidea Biopharmaceuticals has a market capitalization of $60.73 million and generates $660,000.00 in revenue each year. The biopharmaceutical company earns $-10,950,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does Navidea Biopharmaceuticals have?

Navidea Biopharmaceuticals employs 13 workers across the globe.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is www.navidea.com.

Where are Navidea Biopharmaceuticals' headquarters?

Navidea Biopharmaceuticals is headquartered at 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.